Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Health Maintenance Organizations | 23 | 2013 | 656 | 1.070 |
Why?
|
Databases, Factual | 23 | 2024 | 8062 | 1.030 |
Why?
|
Drug Prescriptions | 12 | 2019 | 1662 | 0.990 |
Why?
|
Drug Utilization | 10 | 2018 | 1187 | 0.870 |
Why?
|
Stillbirth | 2 | 2022 | 381 | 0.740 |
Why?
|
Drug Therapy | 7 | 2019 | 504 | 0.740 |
Why?
|
International Classification of Diseases | 7 | 2021 | 933 | 0.700 |
Why?
|
Pregnancy in Diabetics | 1 | 2019 | 198 | 0.590 |
Why?
|
Pregnancy Complications | 6 | 2018 | 2970 | 0.590 |
Why?
|
Pregnancy | 32 | 2024 | 30215 | 0.580 |
Why?
|
Birth Certificates | 4 | 2013 | 71 | 0.550 |
Why?
|
Patient Compliance | 8 | 2018 | 2693 | 0.520 |
Why?
|
Pregnancy Outcome | 7 | 2024 | 2968 | 0.510 |
Why?
|
Abnormalities, Drug-Induced | 4 | 2015 | 336 | 0.490 |
Why?
|
Prenatal Care | 5 | 2016 | 1157 | 0.470 |
Why?
|
Drug Utilization Review | 4 | 2018 | 248 | 0.470 |
Why?
|
Validation Studies as Topic | 2 | 2012 | 162 | 0.470 |
Why?
|
Hypoglycemic Agents | 6 | 2019 | 3107 | 0.430 |
Why?
|
Diabetes, Gestational | 3 | 2019 | 1263 | 0.430 |
Why?
|
Live Birth | 4 | 2022 | 516 | 0.410 |
Why?
|
Pharmacoepidemiology | 4 | 2013 | 351 | 0.410 |
Why?
|
Prescriptions | 2 | 2023 | 388 | 0.390 |
Why?
|
Depressive Disorder | 3 | 2016 | 3711 | 0.380 |
Why?
|
Antidepressive Agents | 5 | 2015 | 2902 | 0.350 |
Why?
|
Hypolipidemic Agents | 4 | 2008 | 608 | 0.350 |
Why?
|
Drug Labeling | 5 | 2014 | 251 | 0.330 |
Why?
|
Diabetes Mellitus | 6 | 2019 | 5889 | 0.330 |
Why?
|
Prenatal Exposure Delayed Effects | 5 | 2019 | 2532 | 0.330 |
Why?
|
Teratogens | 2 | 2008 | 120 | 0.320 |
Why?
|
Antipsychotic Agents | 2 | 2013 | 3076 | 0.310 |
Why?
|
Prescription Drugs | 1 | 2016 | 634 | 0.310 |
Why?
|
Algorithms | 11 | 2021 | 14062 | 0.310 |
Why?
|
Persistent Fetal Circulation Syndrome | 1 | 2009 | 80 | 0.310 |
Why?
|
Estrogen Replacement Therapy | 5 | 2008 | 1206 | 0.300 |
Why?
|
Pregnancy Trimesters | 3 | 2018 | 197 | 0.290 |
Why?
|
Adverse Drug Reaction Reporting Systems | 5 | 2018 | 497 | 0.280 |
Why?
|
Medical Records Systems, Computerized | 5 | 2013 | 1195 | 0.280 |
Why?
|
Diphosphonates | 3 | 2010 | 625 | 0.280 |
Why?
|
Pharmaceutical Preparations | 3 | 2012 | 1084 | 0.280 |
Why?
|
Insurance, Health | 2 | 2012 | 2521 | 0.270 |
Why?
|
Ischemic Attack, Transient | 1 | 2012 | 873 | 0.260 |
Why?
|
United States | 42 | 2024 | 72896 | 0.250 |
Why?
|
Insurance, Pharmaceutical Services | 4 | 2010 | 347 | 0.240 |
Why?
|
Cardiovascular Agents | 2 | 2008 | 850 | 0.230 |
Why?
|
Gestational Age | 3 | 2022 | 3614 | 0.210 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2008 | 519 | 0.210 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2014 | 3251 | 0.210 |
Why?
|
Consumer Product Safety | 2 | 2014 | 122 | 0.210 |
Why?
|
Pregnancy Trimester, First | 2 | 2019 | 917 | 0.210 |
Why?
|
Retrospective Studies | 35 | 2023 | 81505 | 0.200 |
Why?
|
Medical Record Linkage | 3 | 2013 | 286 | 0.200 |
Why?
|
Female | 74 | 2024 | 396050 | 0.200 |
Why?
|
Hospital Information Systems | 1 | 2005 | 395 | 0.200 |
Why?
|
Research Design | 5 | 2019 | 6207 | 0.200 |
Why?
|
Therapeutics | 1 | 2002 | 113 | 0.200 |
Why?
|
Calcitonin | 1 | 2003 | 326 | 0.200 |
Why?
|
Prevalence | 11 | 2016 | 15832 | 0.190 |
Why?
|
Fees, Pharmaceutical | 1 | 2002 | 66 | 0.190 |
Why?
|
Registries | 5 | 2018 | 8320 | 0.190 |
Why?
|
Radiculopathy | 1 | 2023 | 204 | 0.190 |
Why?
|
Rhabdomyolysis | 4 | 2007 | 151 | 0.190 |
Why?
|
Rheumatic Diseases | 1 | 2008 | 620 | 0.190 |
Why?
|
Population Surveillance | 5 | 2014 | 2595 | 0.180 |
Why?
|
Churg-Strauss Syndrome | 3 | 2007 | 74 | 0.180 |
Why?
|
Drug Monitoring | 5 | 2007 | 960 | 0.180 |
Why?
|
Medication Adherence | 5 | 2010 | 2190 | 0.180 |
Why?
|
Endpoint Determination | 2 | 2014 | 591 | 0.180 |
Why?
|
Muscular Diseases | 1 | 2005 | 550 | 0.170 |
Why?
|
Peptic Ulcer | 1 | 2002 | 214 | 0.170 |
Why?
|
Infant, Newborn | 14 | 2016 | 26337 | 0.170 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2003 | 399 | 0.170 |
Why?
|
Medical Records | 4 | 2014 | 1409 | 0.170 |
Why?
|
Product Surveillance, Postmarketing | 4 | 2024 | 463 | 0.170 |
Why?
|
Middle Aged | 50 | 2023 | 223016 | 0.170 |
Why?
|
Adolescent | 26 | 2019 | 88794 | 0.170 |
Why?
|
Adult | 42 | 2023 | 223055 | 0.170 |
Why?
|
Young Adult | 18 | 2023 | 59849 | 0.170 |
Why?
|
Humans | 89 | 2024 | 765823 | 0.160 |
Why?
|
Insurance Claim Review | 5 | 2012 | 744 | 0.160 |
Why?
|
Predictive Value of Tests | 11 | 2013 | 15398 | 0.160 |
Why?
|
Sentinel Surveillance | 2 | 2024 | 292 | 0.160 |
Why?
|
Risk Management | 1 | 2002 | 559 | 0.160 |
Why?
|
Government Regulation | 2 | 2014 | 525 | 0.160 |
Why?
|
Glyburide | 1 | 2019 | 117 | 0.160 |
Why?
|
Gout | 4 | 2010 | 620 | 0.150 |
Why?
|
Antirheumatic Agents | 1 | 2008 | 1362 | 0.150 |
Why?
|
Antihypertensive Agents | 1 | 2008 | 2033 | 0.150 |
Why?
|
Cohort Studies | 22 | 2023 | 41643 | 0.150 |
Why?
|
Fertilization | 1 | 2019 | 197 | 0.150 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2002 | 1127 | 0.150 |
Why?
|
Gout Suppressants | 2 | 2010 | 176 | 0.140 |
Why?
|
Morning Sickness | 1 | 2017 | 6 | 0.140 |
Why?
|
Fractures, Bone | 3 | 2010 | 2041 | 0.140 |
Why?
|
Biomedical Research | 1 | 2012 | 3457 | 0.130 |
Why?
|
Drug Approval | 2 | 2014 | 818 | 0.130 |
Why?
|
Ondansetron | 1 | 2017 | 95 | 0.130 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 258 | 0.130 |
Why?
|
Trimethoprim | 1 | 2015 | 79 | 0.130 |
Why?
|
Maternal Age | 2 | 2016 | 804 | 0.130 |
Why?
|
United States Food and Drug Administration | 4 | 2016 | 1672 | 0.120 |
Why?
|
Antiemetics | 1 | 2017 | 185 | 0.120 |
Why?
|
Hip Fractures | 1 | 2003 | 995 | 0.120 |
Why?
|
Estrogens | 3 | 2008 | 1527 | 0.120 |
Why?
|
Aromatase Inhibitors | 1 | 2019 | 518 | 0.120 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 2 | 2008 | 429 | 0.120 |
Why?
|
Progestins | 2 | 2008 | 300 | 0.120 |
Why?
|
Buprenorphine | 1 | 2022 | 665 | 0.110 |
Why?
|
Schizophrenia | 1 | 2013 | 6970 | 0.110 |
Why?
|
Outpatients | 3 | 2023 | 1591 | 0.110 |
Why?
|
Ambulatory Care | 5 | 2007 | 2776 | 0.110 |
Why?
|
Medical Futility | 1 | 2014 | 136 | 0.110 |
Why?
|
Labor, Induced | 1 | 2014 | 153 | 0.110 |
Why?
|
Pregnancy Trimester, Third | 3 | 2013 | 587 | 0.100 |
Why?
|
Analgesics, Opioid | 3 | 2023 | 3834 | 0.100 |
Why?
|
Potassium | 2 | 2007 | 1311 | 0.100 |
Why?
|
Delivery, Obstetric | 2 | 2013 | 945 | 0.100 |
Why?
|
Homes for the Aged | 1 | 2014 | 273 | 0.100 |
Why?
|
Women's Health | 3 | 2014 | 2082 | 0.100 |
Why?
|
Bone Density Conservation Agents | 2 | 2010 | 791 | 0.100 |
Why?
|
Drug Substitution | 1 | 2014 | 292 | 0.100 |
Why?
|
Aged | 35 | 2023 | 171178 | 0.090 |
Why?
|
Data Mining | 2 | 2013 | 561 | 0.090 |
Why?
|
Anti-Asthmatic Agents | 2 | 2007 | 572 | 0.090 |
Why?
|
Creatinine | 2 | 2007 | 1916 | 0.090 |
Why?
|
Stroke | 3 | 2012 | 9749 | 0.090 |
Why?
|
Data Collection | 2 | 2012 | 3317 | 0.090 |
Why?
|
Perinatal Care | 1 | 2013 | 243 | 0.090 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 1514 | 0.090 |
Why?
|
Quality of Health Care | 1 | 2004 | 4303 | 0.080 |
Why?
|
Medication Errors | 2 | 2005 | 786 | 0.080 |
Why?
|
Epidemiology | 1 | 2011 | 278 | 0.080 |
Why?
|
Infant | 6 | 2021 | 36375 | 0.080 |
Why?
|
Progesterone Congeners | 2 | 2005 | 42 | 0.080 |
Why?
|
Sulfonamides | 2 | 2015 | 1981 | 0.070 |
Why?
|
Antifungal Agents | 1 | 2013 | 769 | 0.070 |
Why?
|
Hyperkalemia | 2 | 2007 | 233 | 0.070 |
Why?
|
Monitoring, Physiologic | 2 | 2006 | 1794 | 0.070 |
Why?
|
Gemfibrozil | 1 | 2007 | 30 | 0.070 |
Why?
|
Opioid-Related Disorders | 1 | 2022 | 2176 | 0.070 |
Why?
|
Calcium Channel Blockers | 1 | 2010 | 685 | 0.070 |
Why?
|
Health Care Surveys | 2 | 2013 | 2424 | 0.070 |
Why?
|
Male | 37 | 2023 | 363740 | 0.070 |
Why?
|
Pharmacies | 2 | 2006 | 171 | 0.070 |
Why?
|
Risk Assessment | 7 | 2015 | 24278 | 0.070 |
Why?
|
Practice Guidelines as Topic | 1 | 2004 | 7416 | 0.070 |
Why?
|
Random Allocation | 1 | 2011 | 2394 | 0.070 |
Why?
|
Nursing Homes | 1 | 2014 | 1084 | 0.070 |
Why?
|
Maternal-Fetal Exchange | 1 | 2009 | 453 | 0.070 |
Why?
|
Fenofibrate | 1 | 2007 | 86 | 0.070 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2014 | 1353 | 0.070 |
Why?
|
Polypharmacy | 2 | 2006 | 306 | 0.070 |
Why?
|
Specialization | 1 | 2011 | 779 | 0.070 |
Why?
|
Hypertension | 3 | 2008 | 8625 | 0.060 |
Why?
|
Bone Resorption | 1 | 2010 | 717 | 0.060 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2009 | 389 | 0.060 |
Why?
|
Child | 9 | 2019 | 80509 | 0.060 |
Why?
|
Correspondence as Topic | 1 | 2005 | 34 | 0.060 |
Why?
|
Gynecology | 1 | 2011 | 534 | 0.060 |
Why?
|
Cooperative Behavior | 1 | 2012 | 1510 | 0.060 |
Why?
|
Clofibric Acid | 1 | 2004 | 8 | 0.060 |
Why?
|
Insulin | 1 | 2019 | 6601 | 0.060 |
Why?
|
Osteoporosis | 3 | 2010 | 1582 | 0.060 |
Why?
|
Sensitivity and Specificity | 5 | 2013 | 14644 | 0.060 |
Why?
|
Amiodarone | 1 | 2006 | 216 | 0.060 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2010 | 1238 | 0.060 |
Why?
|
Aged, 80 and over | 15 | 2015 | 59506 | 0.060 |
Why?
|
Obstetrics | 1 | 2011 | 679 | 0.060 |
Why?
|
Prescription Fees | 1 | 2005 | 153 | 0.060 |
Why?
|
Self Administration | 1 | 2005 | 386 | 0.060 |
Why?
|
Hyperglycemia | 1 | 2013 | 1390 | 0.060 |
Why?
|
Drugs, Generic | 1 | 2009 | 456 | 0.060 |
Why?
|
Macrolides | 1 | 2004 | 204 | 0.050 |
Why?
|
Evaluation Studies as Topic | 1 | 2005 | 1606 | 0.050 |
Why?
|
Hypoglycemia | 1 | 2010 | 896 | 0.050 |
Why?
|
Spironolactone | 1 | 2007 | 415 | 0.050 |
Why?
|
Central Nervous System Stimulants | 1 | 2011 | 1167 | 0.050 |
Why?
|
Insurance Coverage | 1 | 2014 | 1946 | 0.050 |
Why?
|
Sulfonylurea Compounds | 1 | 2004 | 220 | 0.050 |
Why?
|
Anticonvulsants | 1 | 2012 | 1919 | 0.050 |
Why?
|
Irritable Bowel Syndrome | 1 | 2008 | 454 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 7840 | 0.050 |
Why?
|
Health Services Research | 2 | 2013 | 1811 | 0.050 |
Why?
|
Duodenal Ulcer | 1 | 2002 | 117 | 0.050 |
Why?
|
Stomach Ulcer | 1 | 2002 | 118 | 0.050 |
Why?
|
Metformin | 2 | 2013 | 904 | 0.050 |
Why?
|
Delivery of Health Care | 2 | 2015 | 5368 | 0.050 |
Why?
|
Cost Sharing | 1 | 2005 | 409 | 0.050 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2014 | 2184 | 0.050 |
Why?
|
Duodenal Diseases | 1 | 2002 | 101 | 0.050 |
Why?
|
Drug Administration Schedule | 4 | 2010 | 4849 | 0.050 |
Why?
|
Liver Function Tests | 1 | 2003 | 527 | 0.050 |
Why?
|
Antiviral Agents | 1 | 2014 | 3051 | 0.050 |
Why?
|
Wrist Injuries | 1 | 2003 | 215 | 0.050 |
Why?
|
Drug Design | 1 | 2006 | 1040 | 0.050 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2011 | 12235 | 0.040 |
Why?
|
Alendronate | 1 | 2002 | 174 | 0.040 |
Why?
|
Electronics | 1 | 2022 | 314 | 0.040 |
Why?
|
Guideline Adherence | 3 | 2006 | 2235 | 0.040 |
Why?
|
Intestinal Perforation | 1 | 2002 | 254 | 0.040 |
Why?
|
Fetus | 1 | 2007 | 1878 | 0.040 |
Why?
|
Dementia | 1 | 2014 | 2743 | 0.040 |
Why?
|
Thyroid Gland | 1 | 2006 | 1169 | 0.040 |
Why?
|
Back Pain | 1 | 2023 | 546 | 0.040 |
Why?
|
Health Services | 1 | 2005 | 756 | 0.040 |
Why?
|
Epilepsy | 2 | 2012 | 3317 | 0.040 |
Why?
|
Databases as Topic | 3 | 2007 | 472 | 0.040 |
Why?
|
Hospitalization | 4 | 2004 | 10803 | 0.040 |
Why?
|
Sex Distribution | 3 | 2015 | 2268 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2013 | 3987 | 0.040 |
Why?
|
Cardiovascular Diseases | 4 | 2011 | 15645 | 0.040 |
Why?
|
Competitive Medical Plans | 2 | 2009 | 26 | 0.040 |
Why?
|
Chi-Square Distribution | 3 | 2013 | 3435 | 0.040 |
Why?
|
Age Distribution | 3 | 2015 | 2865 | 0.040 |
Why?
|
Insemination, Artificial | 1 | 2019 | 99 | 0.040 |
Why?
|
Allopurinol | 2 | 2010 | 203 | 0.040 |
Why?
|
Opiate Substitution Treatment | 1 | 2022 | 452 | 0.040 |
Why?
|
Seizures | 1 | 2010 | 2997 | 0.040 |
Why?
|
Benzodiazepines | 1 | 2023 | 1135 | 0.040 |
Why?
|
Risk | 4 | 2012 | 9600 | 0.040 |
Why?
|
Cognition | 1 | 2015 | 7045 | 0.030 |
Why?
|
Asthma | 2 | 2007 | 6268 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2015 | 20131 | 0.030 |
Why?
|
Fertility | 1 | 2022 | 768 | 0.030 |
Why?
|
Comorbidity | 5 | 2014 | 10570 | 0.030 |
Why?
|
Spinal Fractures | 1 | 2003 | 703 | 0.030 |
Why?
|
Models, Statistical | 1 | 2011 | 5089 | 0.030 |
Why?
|
Managed Care Programs | 3 | 2008 | 934 | 0.030 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 3718 | 0.030 |
Why?
|
Age Factors | 6 | 2010 | 18380 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2006 | 3716 | 0.030 |
Why?
|
Electronic Health Records | 3 | 2024 | 4864 | 0.030 |
Why?
|
Risk Factors | 8 | 2015 | 74853 | 0.030 |
Why?
|
Anti-Bacterial Agents | 3 | 2015 | 7476 | 0.030 |
Why?
|
Postmenopause | 1 | 2005 | 2517 | 0.030 |
Why?
|
Headache | 1 | 2023 | 1261 | 0.030 |
Why?
|
Chronic Disease | 3 | 2010 | 9355 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2005 | 2687 | 0.030 |
Why?
|
Child, Preschool | 4 | 2011 | 42478 | 0.030 |
Why?
|
Osteoarthritis | 1 | 2002 | 1050 | 0.030 |
Why?
|
Odds Ratio | 3 | 2014 | 9653 | 0.030 |
Why?
|
Mental Status Schedule | 1 | 2014 | 315 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 1 | 2008 | 3229 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2008 | 4056 | 0.030 |
Why?
|
Incidence | 4 | 2018 | 21501 | 0.030 |
Why?
|
Drug Costs | 1 | 2002 | 1193 | 0.030 |
Why?
|
Disease Management | 1 | 2004 | 2532 | 0.030 |
Why?
|
Genital Neoplasms, Female | 1 | 2018 | 533 | 0.030 |
Why?
|
Uric Acid | 2 | 2010 | 808 | 0.030 |
Why?
|
Alzheimer Disease | 1 | 2014 | 8725 | 0.030 |
Why?
|
Confidence Intervals | 2 | 2009 | 2914 | 0.030 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2007 | 2428 | 0.020 |
Why?
|
New England | 2 | 2006 | 1059 | 0.020 |
Why?
|
Obstetric Labor Complications | 1 | 2014 | 239 | 0.020 |
Why?
|
Sex Factors | 4 | 2010 | 10607 | 0.020 |
Why?
|
Pregnancy, Multiple | 1 | 2013 | 216 | 0.020 |
Why?
|
Drug Therapy, Combination | 3 | 2007 | 6304 | 0.020 |
Why?
|
Time Factors | 5 | 2014 | 40109 | 0.020 |
Why?
|
Postpartum Period | 1 | 2018 | 1196 | 0.020 |
Why?
|
Fertilization in Vitro | 1 | 2019 | 1301 | 0.020 |
Why?
|
Liver | 1 | 2006 | 7558 | 0.020 |
Why?
|
Clinical Laboratory Techniques | 2 | 2006 | 747 | 0.020 |
Why?
|
Administration, Oral | 2 | 2010 | 4018 | 0.020 |
Why?
|
Pregnancy Trimester, Second | 1 | 2013 | 737 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2013 | 993 | 0.020 |
Why?
|
Sulfinpyrazone | 1 | 2009 | 15 | 0.020 |
Why?
|
Neoplasms | 1 | 2018 | 22349 | 0.020 |
Why?
|
Probenecid | 1 | 2009 | 72 | 0.020 |
Why?
|
Obesity | 1 | 2011 | 13078 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2014 | 1731 | 0.020 |
Why?
|
Colchicine | 1 | 2010 | 255 | 0.020 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2013 | 391 | 0.020 |
Why?
|
Drug Administration Routes | 1 | 2008 | 152 | 0.020 |
Why?
|
Hospice Care | 1 | 2014 | 678 | 0.020 |
Why?
|
Reference Values | 1 | 2015 | 4911 | 0.020 |
Why?
|
Heart Failure | 1 | 2012 | 11838 | 0.020 |
Why?
|
Naproxen | 1 | 2007 | 99 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2015 | 1422 | 0.020 |
Why?
|
Cross-Sectional Studies | 4 | 2015 | 26276 | 0.020 |
Why?
|
Logistic Models | 3 | 2009 | 13266 | 0.020 |
Why?
|
Infertility, Female | 1 | 2013 | 763 | 0.020 |
Why?
|
Leukotriene Antagonists | 1 | 2007 | 124 | 0.020 |
Why?
|
Hematologic Neoplasms | 1 | 2018 | 1927 | 0.020 |
Why?
|
Breast Neoplasms | 3 | 2018 | 21064 | 0.020 |
Why?
|
Pharmacology, Clinical | 1 | 2006 | 23 | 0.020 |
Why?
|
Insurance Claim Reporting | 1 | 2006 | 166 | 0.020 |
Why?
|
Obstetric Labor, Premature | 1 | 2007 | 268 | 0.020 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2007 | 427 | 0.020 |
Why?
|
Lactones | 1 | 2007 | 316 | 0.020 |
Why?
|
Observation | 1 | 2007 | 309 | 0.020 |
Why?
|
Thyroid Neoplasms | 1 | 2018 | 2354 | 0.020 |
Why?
|
Sulfones | 1 | 2007 | 447 | 0.010 |
Why?
|
Episode of Care | 1 | 2005 | 128 | 0.010 |
Why?
|
Medical Audit | 1 | 2006 | 454 | 0.010 |
Why?
|
Probability | 1 | 2010 | 2475 | 0.010 |
Why?
|
Community Pharmacy Services | 1 | 2004 | 52 | 0.010 |
Why?
|
Program Evaluation | 1 | 2012 | 2501 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2023 | 7872 | 0.010 |
Why?
|
Multivariate Analysis | 2 | 2009 | 12056 | 0.010 |
Why?
|
Death, Sudden, Cardiac | 1 | 2011 | 1567 | 0.010 |
Why?
|
Medicare | 1 | 2002 | 6816 | 0.010 |
Why?
|
Pilot Projects | 1 | 2017 | 8725 | 0.010 |
Why?
|
Treatment Outcome | 5 | 2010 | 65223 | 0.010 |
Why?
|
Financing, Personal | 1 | 2005 | 310 | 0.010 |
Why?
|
Hypothyroidism | 1 | 2008 | 665 | 0.010 |
Why?
|
Proportional Hazards Models | 2 | 2010 | 12520 | 0.010 |
Why?
|
Treatment Refusal | 1 | 2004 | 433 | 0.010 |
Why?
|
Hypercholesterolemia | 1 | 2008 | 1148 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2015 | 39226 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2010 | 2132 | 0.010 |
Why?
|
Melanoma | 1 | 2018 | 5696 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2269 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2007 | 1276 | 0.010 |
Why?
|
Quality Improvement | 1 | 2014 | 3845 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2007 | 22227 | 0.010 |
Why?
|
Drug Industry | 1 | 2005 | 791 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6508 | 0.010 |
Why?
|
Myocardial Infarction | 2 | 2011 | 11506 | 0.010 |
Why?
|
Epidemiologic Research Design | 1 | 2002 | 368 | 0.010 |
Why?
|
Severity of Illness Index | 2 | 2010 | 15881 | 0.010 |
Why?
|
Health Surveys | 1 | 2008 | 4058 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2007 | 1881 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 10723 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13613 | 0.010 |
Why?
|
Pyrazoles | 1 | 2007 | 2031 | 0.010 |
Why?
|
Health Resources | 1 | 2002 | 949 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2007 | 2097 | 0.010 |
Why?
|
Regression Analysis | 1 | 2005 | 6320 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2008 | 3474 | 0.010 |
Why?
|
Pyridines | 1 | 2007 | 2887 | 0.010 |
Why?
|
Mortality | 1 | 2004 | 2910 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2005 | 3686 | 0.010 |
Why?
|
Blood Glucose | 1 | 2006 | 6422 | 0.010 |
Why?
|
Heart Diseases | 1 | 2005 | 2818 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2008 | 14745 | 0.010 |
Why?
|
Coronary Disease | 1 | 2004 | 5923 | 0.010 |
Why?
|
Massachusetts | 1 | 2002 | 8875 | 0.010 |
Why?
|
Health Care Costs | 1 | 2002 | 3240 | 0.000 |
Why?
|
Physicians | 1 | 2005 | 4587 | 0.000 |
Why?
|